Global Disease-Modifying Antirheumatic Drug Market Insights, Forecast to 2026
Disease-Modifying Antirheumatic Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Disease-Modifying Antirheumatic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Disease-Modifying Antirheumatic Drug market is segmented into
The Disease-Modifying Antirheumatic Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Disease-Modifying Antirheumatic Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Disease-Modifying Antirheumatic Drug Market Share Analysis
Disease-Modifying Antirheumatic Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Disease-Modifying Antirheumatic Drug business, the date to enter into the Disease-Modifying Antirheumatic Drug market, Disease-Modifying Antirheumatic Drug product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Disease-Modifying Antirheumatic Drug market is segmented into
- Non-Steroidal Anti-Inflammatory Drugs
- Steroidal Anti-Inflammatory Drugs
- Slow Acting Drug
- Immunological Preparation
- Pharmaceutical Industry
- Hospital and Clinic
- Other
The Disease-Modifying Antirheumatic Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Disease-Modifying Antirheumatic Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Disease-Modifying Antirheumatic Drug Market Share Analysis
Disease-Modifying Antirheumatic Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Disease-Modifying Antirheumatic Drug business, the date to enter into the Disease-Modifying Antirheumatic Drug market, Disease-Modifying Antirheumatic Drug product introduction, recent developments, etc.
The major vendors covered:
- AbbVie
- Amgen
- Pfizer
- Roche Holding AG
- Novartis International AG
- Johnson & Johnson
- Bristol-Myers Squibb
- Merck
- UCB S.A.
- Eli Lilly and Company
1 STUDY COVERAGE
1.1 Disease-Modifying Antirheumatic Drug Product Introduction
1.2 Market Segments
1.3 Key Disease-Modifying Antirheumatic Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Type
1.4.2 Non-Steroidal Anti-Inflammatory Drugs
1.4.3 Steroidal Anti-Inflammatory Drugs
1.4.4 Slow Acting Drug
1.4.5 Immunological Preparation
1.5 Market by Application
1.5.1 Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Application
1.5.2 Pharmaceutical Industry
1.5.3 Hospital and Clinic
1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Disease-Modifying Antirheumatic Drug Industry Impact
1.6.1 How the Covid-19 is Affecting the Disease-Modifying Antirheumatic Drug Industry
1.6.1.1 Disease-Modifying Antirheumatic Drug Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Disease-Modifying Antirheumatic Drug Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Disease-Modifying Antirheumatic Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Disease-Modifying Antirheumatic Drug Market Size Estimates and Forecasts
2.1.1 Global Disease-Modifying Antirheumatic Drug Revenue 2015-2026
2.1.2 Global Disease-Modifying Antirheumatic Drug Sales 2015-2026
2.2 Disease-Modifying Antirheumatic Drug Market Size by Region: 2020 Versus 2026
2.2.1 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL DISEASE-MODIFYING ANTIRHEUMATIC DRUG COMPETITOR LANDSCAPE BY PLAYERS
3.1 Disease-Modifying Antirheumatic Drug Sales by Manufacturers
3.1.1 Disease-Modifying Antirheumatic Drug Sales by Manufacturers (2015-2020)
3.1.2 Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Disease-Modifying Antirheumatic Drug Revenue by Manufacturers
3.2.1 Disease-Modifying Antirheumatic Drug Revenue by Manufacturers (2015-2020)
3.2.2 Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Disease-Modifying Antirheumatic Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Disease-Modifying Antirheumatic Drug Revenue in 2019
3.2.5 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Disease-Modifying Antirheumatic Drug Price by Manufacturers
3.4 Disease-Modifying Antirheumatic Drug Manufacturing Base Distribution, Product Types
3.4.1 Disease-Modifying Antirheumatic Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Disease-Modifying Antirheumatic Drug Product Type
3.4.3 Date of International Manufacturers Enter into Disease-Modifying Antirheumatic Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Disease-Modifying Antirheumatic Drug Market Size by Type (2015-2020)
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020)
4.1.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2015-2020)
4.1.3 Disease-Modifying Antirheumatic Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Disease-Modifying Antirheumatic Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2021-2026)
4.2.3 Disease-Modifying Antirheumatic Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Disease-Modifying Antirheumatic Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Disease-Modifying Antirheumatic Drug Market Size by Application (2015-2020)
5.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020)
5.1.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2015-2020)
5.1.3 Disease-Modifying Antirheumatic Drug Price by Application (2015-2020)
5.2 Disease-Modifying Antirheumatic Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Disease-Modifying Antirheumatic Drug Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Disease-Modifying Antirheumatic Drug by Country
6.1.1 North America Disease-Modifying Antirheumatic Drug Sales by Country
6.1.2 North America Disease-Modifying Antirheumatic Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
6.3 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
7 EUROPE
7.1 Europe Disease-Modifying Antirheumatic Drug by Country
7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country
7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
7.3 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Disease-Modifying Antirheumatic Drug by Region
8.1.1 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region
8.1.2 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
8.3 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Disease-Modifying Antirheumatic Drug by Country
9.1.1 Latin America Disease-Modifying Antirheumatic Drug Sales by Country
9.1.2 Latin America Disease-Modifying Antirheumatic Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
9.3 Central & South America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Disease-Modifying Antirheumatic Drug by Country
10.1.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country
10.1.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
10.3 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Disease-Modifying Antirheumatic Drug Products Offered
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Description, Business Overview and Total Revenue
11.2.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Amgen Disease-Modifying Antirheumatic Drug Products Offered
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description, Business Overview and Total Revenue
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Disease-Modifying Antirheumatic Drug Products Offered
11.3.5 Pfizer Recent Development
11.4 Roche Holding AG
11.4.1 Roche Holding AG Corporation Information
11.4.2 Roche Holding AG Description, Business Overview and Total Revenue
11.4.3 Roche Holding AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Products Offered
11.4.5 Roche Holding AG Recent Development
11.5 Novartis International AG
11.5.1 Novartis International AG Corporation Information
11.5.2 Novartis International AG Description, Business Overview and Total Revenue
11.5.3 Novartis International AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Products Offered
11.5.5 Novartis International AG Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Description, Business Overview and Total Revenue
11.6.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Products Offered
11.6.5 Johnson & Johnson Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Corporation Information
11.7.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
11.7.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Products Offered
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Description, Business Overview and Total Revenue
11.8.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Merck Disease-Modifying Antirheumatic Drug Products Offered
11.8.5 Merck Recent Development
11.9 UCB S.A.
11.9.1 UCB S.A. Corporation Information
11.9.2 UCB S.A. Description, Business Overview and Total Revenue
11.9.3 UCB S.A. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Products Offered
11.9.5 UCB S.A. Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Corporation Information
11.10.2 Eli Lilly and Company Description, Business Overview and Total Revenue
11.10.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Products Offered
11.10.5 Eli Lilly and Company Recent Development
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Disease-Modifying Antirheumatic Drug Products Offered
11.1.5 AbbVie Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Disease-Modifying Antirheumatic Drug Market Estimates and Projections by Region
12.1.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Regions 2021-2026
12.2 North America Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.2.1 North America: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.2.2 North America: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.2.3 North America: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.3.2 Europe: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Disease-Modifying Antirheumatic Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Disease-Modifying Antirheumatic Drug Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Disease-Modifying Antirheumatic Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Disease-Modifying Antirheumatic Drug Product Introduction
1.2 Market Segments
1.3 Key Disease-Modifying Antirheumatic Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Type
1.4.2 Non-Steroidal Anti-Inflammatory Drugs
1.4.3 Steroidal Anti-Inflammatory Drugs
1.4.4 Slow Acting Drug
1.4.5 Immunological Preparation
1.5 Market by Application
1.5.1 Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Application
1.5.2 Pharmaceutical Industry
1.5.3 Hospital and Clinic
1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Disease-Modifying Antirheumatic Drug Industry Impact
1.6.1 How the Covid-19 is Affecting the Disease-Modifying Antirheumatic Drug Industry
1.6.1.1 Disease-Modifying Antirheumatic Drug Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Disease-Modifying Antirheumatic Drug Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Disease-Modifying Antirheumatic Drug Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Disease-Modifying Antirheumatic Drug Market Size Estimates and Forecasts
2.1.1 Global Disease-Modifying Antirheumatic Drug Revenue 2015-2026
2.1.2 Global Disease-Modifying Antirheumatic Drug Sales 2015-2026
2.2 Disease-Modifying Antirheumatic Drug Market Size by Region: 2020 Versus 2026
2.2.1 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL DISEASE-MODIFYING ANTIRHEUMATIC DRUG COMPETITOR LANDSCAPE BY PLAYERS
3.1 Disease-Modifying Antirheumatic Drug Sales by Manufacturers
3.1.1 Disease-Modifying Antirheumatic Drug Sales by Manufacturers (2015-2020)
3.1.2 Disease-Modifying Antirheumatic Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Disease-Modifying Antirheumatic Drug Revenue by Manufacturers
3.2.1 Disease-Modifying Antirheumatic Drug Revenue by Manufacturers (2015-2020)
3.2.2 Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Disease-Modifying Antirheumatic Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Disease-Modifying Antirheumatic Drug Revenue in 2019
3.2.5 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Disease-Modifying Antirheumatic Drug Price by Manufacturers
3.4 Disease-Modifying Antirheumatic Drug Manufacturing Base Distribution, Product Types
3.4.1 Disease-Modifying Antirheumatic Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Disease-Modifying Antirheumatic Drug Product Type
3.4.3 Date of International Manufacturers Enter into Disease-Modifying Antirheumatic Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Disease-Modifying Antirheumatic Drug Market Size by Type (2015-2020)
4.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020)
4.1.2 Global Disease-Modifying Antirheumatic Drug Revenue by Type (2015-2020)
4.1.3 Disease-Modifying Antirheumatic Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Disease-Modifying Antirheumatic Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2021-2026)
4.2.3 Disease-Modifying Antirheumatic Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Disease-Modifying Antirheumatic Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Disease-Modifying Antirheumatic Drug Market Size by Application (2015-2020)
5.1.1 Global Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020)
5.1.2 Global Disease-Modifying Antirheumatic Drug Revenue by Application (2015-2020)
5.1.3 Disease-Modifying Antirheumatic Drug Price by Application (2015-2020)
5.2 Disease-Modifying Antirheumatic Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Disease-Modifying Antirheumatic Drug Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Disease-Modifying Antirheumatic Drug by Country
6.1.1 North America Disease-Modifying Antirheumatic Drug Sales by Country
6.1.2 North America Disease-Modifying Antirheumatic Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
6.3 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
7 EUROPE
7.1 Europe Disease-Modifying Antirheumatic Drug by Country
7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Country
7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
7.3 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Disease-Modifying Antirheumatic Drug by Region
8.1.1 Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region
8.1.2 Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
8.3 Asia Pacific Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Disease-Modifying Antirheumatic Drug by Country
9.1.1 Latin America Disease-Modifying Antirheumatic Drug Sales by Country
9.1.2 Latin America Disease-Modifying Antirheumatic Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
9.3 Central & South America Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Disease-Modifying Antirheumatic Drug by Country
10.1.1 Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country
10.1.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Type
10.3 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Disease-Modifying Antirheumatic Drug Products Offered
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Description, Business Overview and Total Revenue
11.2.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Amgen Disease-Modifying Antirheumatic Drug Products Offered
11.2.5 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description, Business Overview and Total Revenue
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Disease-Modifying Antirheumatic Drug Products Offered
11.3.5 Pfizer Recent Development
11.4 Roche Holding AG
11.4.1 Roche Holding AG Corporation Information
11.4.2 Roche Holding AG Description, Business Overview and Total Revenue
11.4.3 Roche Holding AG Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Products Offered
11.4.5 Roche Holding AG Recent Development
11.5 Novartis International AG
11.5.1 Novartis International AG Corporation Information
11.5.2 Novartis International AG Description, Business Overview and Total Revenue
11.5.3 Novartis International AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Products Offered
11.5.5 Novartis International AG Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Description, Business Overview and Total Revenue
11.6.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Products Offered
11.6.5 Johnson & Johnson Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Corporation Information
11.7.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
11.7.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Products Offered
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Merck
11.8.1 Merck Corporation Information
11.8.2 Merck Description, Business Overview and Total Revenue
11.8.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Merck Disease-Modifying Antirheumatic Drug Products Offered
11.8.5 Merck Recent Development
11.9 UCB S.A.
11.9.1 UCB S.A. Corporation Information
11.9.2 UCB S.A. Description, Business Overview and Total Revenue
11.9.3 UCB S.A. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Products Offered
11.9.5 UCB S.A. Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Corporation Information
11.10.2 Eli Lilly and Company Description, Business Overview and Total Revenue
11.10.3 Eli Lilly and Company Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Products Offered
11.10.5 Eli Lilly and Company Recent Development
11.1 AbbVie
11.1.1 AbbVie Corporation Information
11.1.2 AbbVie Description, Business Overview and Total Revenue
11.1.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AbbVie Disease-Modifying Antirheumatic Drug Products Offered
11.1.5 AbbVie Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Disease-Modifying Antirheumatic Drug Market Estimates and Projections by Region
12.1.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Regions 2021-2026
12.2 North America Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.2.1 North America: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.2.2 North America: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.2.3 North America: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.3.2 Europe: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Disease-Modifying Antirheumatic Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Disease-Modifying Antirheumatic Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Disease-Modifying Antirheumatic Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Disease-Modifying Antirheumatic Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Disease-Modifying Antirheumatic Drug Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Disease-Modifying Antirheumatic Drug Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Disease-Modifying Antirheumatic Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Disease-Modifying Antirheumatic Drug Market Segments
Table 2. Ranking of Global Top Disease-Modifying Antirheumatic Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million)
Table 4. Major Manufacturers of Non-Steroidal Anti-Inflammatory Drugs
Table 5. Major Manufacturers of Steroidal Anti-Inflammatory Drugs
Table 6. Major Manufacturers of Slow Acting Drug
Table 7. Major Manufacturers of Immunological Preparation
Table 8. COVID-19 Impact Global Market: (Four Disease-Modifying Antirheumatic Drug Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Disease-Modifying Antirheumatic Drug Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Disease-Modifying Antirheumatic Drug Players to Combat Covid-19 Impact
Table 13. Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Application 2020-2026 (MT)
Table 14. Global Disease-Modifying Antirheumatic Drug Market Size by Region (MT) & (US$ Million): 2020 VS 2026
Table 15. Global Disease-Modifying Antirheumatic Drug Sales by Regions 2015-2020 (MT)
Table 16. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Regions (2015-2020)
Table 17. Global Disease-Modifying Antirheumatic Drug Revenue by Regions 2015-2020 (US$ Million)
Table 18. Global Disease-Modifying Antirheumatic Drug Sales by Manufacturers (2015-2020) (MT)
Table 19. Global Disease-Modifying Antirheumatic Drug Sales Share by Manufacturers (2015-2020)
Table 20. Global Disease-Modifying Antirheumatic Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 21. Global Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2019)
Table 22. Disease-Modifying Antirheumatic Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 23. Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2015-2020)
Table 24. Key Manufacturers Disease-Modifying Antirheumatic Drug Price (2015-2020) (USD/MT)
Table 25. Disease-Modifying Antirheumatic Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Disease-Modifying Antirheumatic Drug Product Type
Table 27. Date of International Manufacturers Enter into Disease-Modifying Antirheumatic Drug Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 30. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2015-2020)
Table 31. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2015-2020) (US$ Million)
Table 32. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2015-2020)
Table 33. Disease-Modifying Antirheumatic Drug Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 34. Global Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 35. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2015-2020)
Table 36. North America Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 37. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 38. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 39. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 40. North America Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 41. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 42. North America Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 43. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 44. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 45. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 46. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 47. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 48. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 49. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 50. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 51. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 52. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2015-2020) (MT)
Table 53. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020)
Table 54. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2015-2020) (US$ Million)
Table 55. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020)
Table 56. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 57. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 58. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 59. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 60. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 61. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 62. Latin Americaa Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 63. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 64. Latin America Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 65. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 66. Latin America Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 67. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 68. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 69. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 70. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 71. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 73. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 74. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 75. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 76. AbbVie Corporation Information
Table 77. AbbVie Description and Major Businesses
Table 78. AbbVie Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 79. AbbVie Product
Table 80. AbbVie Recent Development
Table 81. Amgen Corporation Information
Table 82. Amgen Description and Major Businesses
Table 83. Amgen Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. Amgen Product
Table 85. Amgen Recent Development
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. Pfizer Product
Table 90. Pfizer Recent Development
Table 91. Roche Holding AG Corporation Information
Table 92. Roche Holding AG Description and Major Businesses
Table 93. Roche Holding AG Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Roche Holding AG Product
Table 95. Roche Holding AG Recent Development
Table 96. Novartis International AG Corporation Information
Table 97. Novartis International AG Description and Major Businesses
Table 98. Novartis International AG Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. Novartis International AG Product
Table 100. Novartis International AG Recent Development
Table 101. Johnson & Johnson Corporation Information
Table 102. Johnson & Johnson Description and Major Businesses
Table 103. Johnson & Johnson Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 104. Johnson & Johnson Product
Table 105. Johnson & Johnson Recent Development
Table 106. Bristol-Myers Squibb Corporation Information
Table 107. Bristol-Myers Squibb Description and Major Businesses
Table 108. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 109. Bristol-Myers Squibb Product
Table 110. Bristol-Myers Squibb Recent Development
Table 111. Merck Corporation Information
Table 112. Merck Description and Major Businesses
Table 113. Merck Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 114. Merck Product
Table 115. Merck Recent Development
Table 116. UCB S.A. Corporation Information
Table 117. UCB S.A. Description and Major Businesses
Table 118. UCB S.A. Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 119. UCB S.A. Product
Table 120. UCB S.A. Recent Development
Table 121. Eli Lilly and Company Corporation Information
Table 122. Eli Lilly and Company Description and Major Businesses
Table 123. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 124. Eli Lilly and Company Product
Table 125. Eli Lilly and Company Recent Development
Table 126. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Regions (2021-2026) (MT)
Table 127. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Regions (2021-2026)
Table 128. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 129. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 130. North America: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 131. North America: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Europe: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 133. Europe: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 134. Asia Pacific: Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2021-2026) (MT)
Table 135. Asia Pacific: Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 136. Latin America: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 137. Latin America: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Middle East and Africa: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 139. Middle East and Africa: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 141. Key Challenges
Table 142. Market Risks
Table 143. Main Points Interviewed from Key Disease-Modifying Antirheumatic Drug Players
Table 144. Disease-Modifying Antirheumatic Drug Customers List
Table 145. Disease-Modifying Antirheumatic Drug Distributors List
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
Table 1. Disease-Modifying Antirheumatic Drug Market Segments
Table 2. Ranking of Global Top Disease-Modifying Antirheumatic Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Type 2020-2026 (MT) & (US$ Million)
Table 4. Major Manufacturers of Non-Steroidal Anti-Inflammatory Drugs
Table 5. Major Manufacturers of Steroidal Anti-Inflammatory Drugs
Table 6. Major Manufacturers of Slow Acting Drug
Table 7. Major Manufacturers of Immunological Preparation
Table 8. COVID-19 Impact Global Market: (Four Disease-Modifying Antirheumatic Drug Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Disease-Modifying Antirheumatic Drug Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Disease-Modifying Antirheumatic Drug Players to Combat Covid-19 Impact
Table 13. Global Disease-Modifying Antirheumatic Drug Market Size Growth Rate by Application 2020-2026 (MT)
Table 14. Global Disease-Modifying Antirheumatic Drug Market Size by Region (MT) & (US$ Million): 2020 VS 2026
Table 15. Global Disease-Modifying Antirheumatic Drug Sales by Regions 2015-2020 (MT)
Table 16. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Regions (2015-2020)
Table 17. Global Disease-Modifying Antirheumatic Drug Revenue by Regions 2015-2020 (US$ Million)
Table 18. Global Disease-Modifying Antirheumatic Drug Sales by Manufacturers (2015-2020) (MT)
Table 19. Global Disease-Modifying Antirheumatic Drug Sales Share by Manufacturers (2015-2020)
Table 20. Global Disease-Modifying Antirheumatic Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 21. Global Disease-Modifying Antirheumatic Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2019)
Table 22. Disease-Modifying Antirheumatic Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 23. Disease-Modifying Antirheumatic Drug Revenue Share by Manufacturers (2015-2020)
Table 24. Key Manufacturers Disease-Modifying Antirheumatic Drug Price (2015-2020) (USD/MT)
Table 25. Disease-Modifying Antirheumatic Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Disease-Modifying Antirheumatic Drug Product Type
Table 27. Date of International Manufacturers Enter into Disease-Modifying Antirheumatic Drug Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 30. Global Disease-Modifying Antirheumatic Drug Sales Share by Type (2015-2020)
Table 31. Global Disease-Modifying Antirheumatic Drug Revenue by Type (2015-2020) (US$ Million)
Table 32. Global Disease-Modifying Antirheumatic Drug Revenue Share by Type (2015-2020)
Table 33. Disease-Modifying Antirheumatic Drug Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 34. Global Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 35. Global Disease-Modifying Antirheumatic Drug Sales Share by Application (2015-2020)
Table 36. North America Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 37. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 38. North America Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 39. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 40. North America Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 41. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 42. North America Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 43. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 44. Europe Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 45. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 46. Europe Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 47. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 48. Europe Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 49. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 50. Europe Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 51. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 52. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Region (2015-2020) (MT)
Table 53. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020)
Table 54. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue by Region (2015-2020) (US$ Million)
Table 55. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020)
Table 56. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 57. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 58. Asia Pacific Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 59. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 60. Latin America Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 61. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 62. Latin Americaa Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 63. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 64. Latin America Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 65. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 66. Latin America Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 67. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 68. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Country (2015-2020) (MT)
Table 69. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country (2015-2020)
Table 70. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue by Country (2015-2020) (US$ Million)
Table 71. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Type (2015-2020) (MT)
Table 73. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Table 74. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales by Application (2015-2020) (MT)
Table 75. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Table 76. AbbVie Corporation Information
Table 77. AbbVie Description and Major Businesses
Table 78. AbbVie Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 79. AbbVie Product
Table 80. AbbVie Recent Development
Table 81. Amgen Corporation Information
Table 82. Amgen Description and Major Businesses
Table 83. Amgen Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. Amgen Product
Table 85. Amgen Recent Development
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. Pfizer Product
Table 90. Pfizer Recent Development
Table 91. Roche Holding AG Corporation Information
Table 92. Roche Holding AG Description and Major Businesses
Table 93. Roche Holding AG Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Roche Holding AG Product
Table 95. Roche Holding AG Recent Development
Table 96. Novartis International AG Corporation Information
Table 97. Novartis International AG Description and Major Businesses
Table 98. Novartis International AG Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. Novartis International AG Product
Table 100. Novartis International AG Recent Development
Table 101. Johnson & Johnson Corporation Information
Table 102. Johnson & Johnson Description and Major Businesses
Table 103. Johnson & Johnson Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 104. Johnson & Johnson Product
Table 105. Johnson & Johnson Recent Development
Table 106. Bristol-Myers Squibb Corporation Information
Table 107. Bristol-Myers Squibb Description and Major Businesses
Table 108. Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 109. Bristol-Myers Squibb Product
Table 110. Bristol-Myers Squibb Recent Development
Table 111. Merck Corporation Information
Table 112. Merck Description and Major Businesses
Table 113. Merck Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 114. Merck Product
Table 115. Merck Recent Development
Table 116. UCB S.A. Corporation Information
Table 117. UCB S.A. Description and Major Businesses
Table 118. UCB S.A. Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 119. UCB S.A. Product
Table 120. UCB S.A. Recent Development
Table 121. Eli Lilly and Company Corporation Information
Table 122. Eli Lilly and Company Description and Major Businesses
Table 123. Eli Lilly and Company Disease-Modifying Antirheumatic Drug Production (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 124. Eli Lilly and Company Product
Table 125. Eli Lilly and Company Recent Development
Table 126. Global Disease-Modifying Antirheumatic Drug Sales Forecast by Regions (2021-2026) (MT)
Table 127. Global Disease-Modifying Antirheumatic Drug Sales Market Share Forecast by Regions (2021-2026)
Table 128. Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 129. Global Disease-Modifying Antirheumatic Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 130. North America: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 131. North America: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Europe: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 133. Europe: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 134. Asia Pacific: Disease-Modifying Antirheumatic Drug Sales Forecast by Region (2021-2026) (MT)
Table 135. Asia Pacific: Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 136. Latin America: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 137. Latin America: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Middle East and Africa: Disease-Modifying Antirheumatic Drug Sales Forecast by Country (2021-2026) (MT)
Table 139. Middle East and Africa: Disease-Modifying Antirheumatic Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 140. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 141. Key Challenges
Table 142. Market Risks
Table 143. Main Points Interviewed from Key Disease-Modifying Antirheumatic Drug Players
Table 144. Disease-Modifying Antirheumatic Drug Customers List
Table 145. Disease-Modifying Antirheumatic Drug Distributors List
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Disease-Modifying Antirheumatic Drug Product Picture
Figure 2. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Non-Steroidal Anti-Inflammatory Drugs Product Picture
Figure 4. Steroidal Anti-Inflammatory Drugs Product Picture
Figure 5. Slow Acting Drug Product Picture
Figure 6. Immunological Preparation Product Picture
Figure 7. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Pharmaceutical Industry
Figure 9. Hospital and Clinic
Figure 10. Other
Figure 11. Disease-Modifying Antirheumatic Drug Report Years Considered
Figure 12. Global Disease-Modifying Antirheumatic Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Disease-Modifying Antirheumatic Drug Sales 2015-2026 (MT)
Figure 14. Global Disease-Modifying Antirheumatic Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2019
Figure 17. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in 2019
Figure 19. Global Disease-Modifying Antirheumatic Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Disease-Modifying Antirheumatic Drug Revenue in 2019
Figure 21. Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 24. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type in 2019
Figure 26. Global Disease-Modifying Antirheumatic Drug Market Share by Price Range (2015-2020)
Figure 27. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 29. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application in 2019
Figure 31. North America Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 32. North America Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 34. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 36. U.S. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 38. Canada Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 40. North America Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 41. Europe Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 42. Europe Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 44. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 45. Germany Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 46. Germany Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 48. France Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 50. U.K. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 52. Italy Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 54. Russia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 56. Europe Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 57. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 58. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in 2019
Figure 61. China Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 62. China Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 64. Japan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 66. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 68. India Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 70. Australia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 72. Taiwan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 74. Indonesia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 76. Thailand Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 78. Malaysia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 80. Philippines Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 82. Vietnam Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 84. Asia Pacific Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 85. Latin America Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 86. Latin America Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 88. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 90. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 92. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 94. Argentina Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 96. Latin America Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 98. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 102. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 104. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 106. U.A.E Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 109. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Novartis International AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. UCB S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. North America Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 120. North America Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Europe Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 122. Europe Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 124. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Latin America Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 126. Latin America Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 128. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Porter's Five Forces Analysis
Figure 130. Channels of Distribution
Figure 131. Distributors Profiles
Figure 132. Bottom-up and Top-down Approaches for This Report
Figure 133. Data Triangulation
Figure 134. Key Executives Interviewed
Figure 1. Disease-Modifying Antirheumatic Drug Product Picture
Figure 2. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Non-Steroidal Anti-Inflammatory Drugs Product Picture
Figure 4. Steroidal Anti-Inflammatory Drugs Product Picture
Figure 5. Slow Acting Drug Product Picture
Figure 6. Immunological Preparation Product Picture
Figure 7. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2020 & 2026
Figure 8. Pharmaceutical Industry
Figure 9. Hospital and Clinic
Figure 10. Other
Figure 11. Disease-Modifying Antirheumatic Drug Report Years Considered
Figure 12. Global Disease-Modifying Antirheumatic Drug Market Size 2015-2026 (US$ Million)
Figure 13. Global Disease-Modifying Antirheumatic Drug Sales 2015-2026 (MT)
Figure 14. Global Disease-Modifying Antirheumatic Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2015-2020)
Figure 16. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2019
Figure 17. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2015-2020)
Figure 18. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in 2019
Figure 19. Global Disease-Modifying Antirheumatic Drug Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Disease-Modifying Antirheumatic Drug Revenue in 2019
Figure 21. Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2015-2020)
Figure 23. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type in 2019
Figure 24. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2015-2020)
Figure 25. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type in 2019
Figure 26. Global Disease-Modifying Antirheumatic Drug Market Share by Price Range (2015-2020)
Figure 27. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2015-2020)
Figure 28. Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application in 2019
Figure 29. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2015-2020)
Figure 30. Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application in 2019
Figure 31. North America Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 32. North America Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 34. North America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 35. U.S. Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 36. U.S. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 38. Canada Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 40. North America Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 41. Europe Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 42. Europe Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 44. Europe Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 45. Germany Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 46. Germany Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 48. France Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 50. U.K. Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 52. Italy Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 54. Russia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 56. Europe Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 57. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 58. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Market Share by Region in 2019
Figure 60. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Market Share by Region in 2019
Figure 61. China Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 62. China Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 64. Japan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 66. South Korea Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 68. India Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 70. Australia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 72. Taiwan Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 74. Indonesia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 76. Thailand Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 78. Malaysia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 80. Philippines Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 82. Vietnam Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 84. Asia Pacific Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 85. Latin America Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 86. Latin America Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 88. Latin America Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 89. Mexico Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 90. Mexico Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 92. Brazil Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 94. Argentina Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 96. Latin America Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 97. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Growth Rate 2015-2020 (MT)
Figure 98. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Market Share by Country in 2019
Figure 101. Turkey Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 102. Turkey Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 104. Saudi Arabia Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Disease-Modifying Antirheumatic Drug Sales Growth Rate (2015-2020) (MT)
Figure 106. U.A.E Disease-Modifying Antirheumatic Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Disease-Modifying Antirheumatic Drug Market Share by Type in 2019
Figure 108. Middle East and Africa Disease-Modifying Antirheumatic Drug Market Share by Application in 2019
Figure 109. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Roche Holding AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Novartis International AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. UCB S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. North America Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 120. North America Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Europe Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 122. Europe Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Asia Pacific Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 124. Asia Pacific Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Latin America Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 126. Latin America Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Middle East and Africa Disease-Modifying Antirheumatic Drug Sales Growth Rate Forecast (2021-2026) (MT)
Figure 128. Middle East and Africa Disease-Modifying Antirheumatic Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Porter's Five Forces Analysis
Figure 130. Channels of Distribution
Figure 131. Distributors Profiles
Figure 132. Bottom-up and Top-down Approaches for This Report
Figure 133. Data Triangulation
Figure 134. Key Executives Interviewed
